Endo International (NASDAQ:ENDP) PT Lowered to $4.75 at Cantor Fitzgerald

Endo International (NASDAQ:ENDP) (TSE:ENL) had its price target dropped by investment analysts at Cantor Fitzgerald from $18.00 to $4.75 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a “neutral” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 6.26% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Endo International from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Piper Jaffray Companies reissued a “hold” rating on shares of Endo International in a report on Friday, March 1st. Leerink Swann lowered Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Svb Leerink lowered Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Finally, ValuEngine lowered Endo International from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $13.57.

Endo International stock opened at $4.47 on Wednesday. Endo International has a one year low of $4.18 and a one year high of $18.50. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 1.62 and a beta of 1.35.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.11. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The company had revenue of $720.00 million during the quarter, compared to analysts’ expectations of $692.31 million. During the same period last year, the business posted $0.67 earnings per share. The firm’s revenue was up 2.9% compared to the same quarter last year. As a group, equities research analysts predict that Endo International will post 2.17 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. LS Investment Advisors LLC acquired a new stake in Endo International in the fourth quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund acquired a new stake in Endo International in the fourth quarter valued at approximately $76,000. Signition LP acquired a new stake in Endo International in the first quarter valued at approximately $139,000. Neuburgh Advisers LLC grew its holdings in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after purchasing an additional 3,036 shares during the period. Finally, Factorial Partners LLC acquired a new stake in Endo International in the first quarter valued at approximately $193,000. 93.59% of the stock is currently owned by institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: Trading based on a resistance level

The Fly

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.